Positron Emission Tomography Market Report by Product Type, Detector Type, Application, End-User Countries and Company Analysis 2026-2034

Advanced Molecular Diagnostics: PET Market Size, AI-Driven Reconstruction, and Long-Term Projections

Positron Emission Tomography (PET) Market is projected to grow from US$ 2.22 Billion in 2025 to US$ 3.70 Billion by 2034, registering a Compound Annual Growth Rate (CAGR) of 5.83% during 2026–2034. Market growth is driven by the rising prevalence of cancer, cardiovascular diseases, and neurological disorders, increasing demand for early and accurate diagnostic imaging, and continuous advancements in hybrid PET/CT and PET/MRI technologies. Expanding healthcare infrastructure, growing adoption of precision medicine, and increased investments in molecular imaging are expected to further support global market expansion during the forecast period.

What Is Positron Emission Tomography? A Guide to Its Clinical Uses and Global Popularity

Positron Emission Tomography (PET) is an advanced nuclear medicine imaging technique that uses small amounts of radioactive tracers, known as radiopharmaceuticals, to visualize metabolic and physiological processes within the body. During a PET scan, the tracer accumulates in tissues with high metabolic activity, allowing physicians to detect abnormalities that may not be visible using conventional imaging methods. PET is commonly combined with Computed Tomography (PET/CT) or Magnetic Resonance Imaging (PET/MRI) to provide both functional and anatomical information, improving diagnostic accuracy. The technology is widely used for cancer detection, staging, treatment planning, and monitoring therapeutic response. It also plays a crucial role in diagnosing neurological disorders such as Alzheimer's disease, epilepsy, Parkinson's disease, and cardiovascular conditions by evaluating blood flow and heart muscle viability.

Worldwide, PET imaging has gained widespread popularity due to the increasing burden of chronic diseases and the growing emphasis on early and precise diagnosis. Hospitals, diagnostic imaging centers, and research institutions are expanding PET capabilities to support personalized medicine and targeted therapies. Continuous advancements in radiotracer development, digital PET scanners, artificial intelligence-assisted image analysis, and hybrid imaging systems have significantly improved scan quality and diagnostic efficiency. Rising healthcare investments, expanding oncology screening programs, and increasing adoption of molecular imaging technologies continue to drive the global popularity of Positron Emission Tomography across both developed and emerging healthcare markets.

New Cancer Cases (2026)

• Total estimated new cancer cases: Approximately 2.11 million.
• Other cancer types: 1,068,180 cases (51%), representing the largest share of all new cancer diagnoses.
• Prostate cancer: 333,830 cases (16%), the most commonly diagnosed individual cancer type.
• Breast cancer: 324,580 cases (15%), accounting for the second-largest share of new cases.
• Lung and bronchus cancer: 229,410 cases (11%), remaining one of the leading cancer diagnoses.
• Colon and rectum cancer: 158,850 cases (8%), among the most frequently diagnosed gastrointestinal cancers.

Cancer Deaths (2026)

• Total estimated cancer deaths: Approximately 626,140.
• Other cancer types: 350,510 deaths (56%), representing the largest share of cancer mortality.
• Lung and bronchus cancer: 124,990 deaths (20%), the leading cause of cancer-related deaths.
• Colon and rectum cancer: 55,230 deaths (9%), the second-leading cause of cancer mortality among the listed cancers.
• Pancreatic cancer: 52,740 deaths (8%), reflecting its high mortality despite lower incidence.
• Breast cancer: 42,670 deaths (7%), remaining a significant contributor to overall cancer mortality.

Growth Driver

Rising Global Cancer Burden Driving PET Imaging Demand

The increasing prevalence of cancer is one of the strongest growth drivers for the Positron Emission Tomography (PET) market. According to global health estimates, more than 20 million new cancer cases are diagnosed worldwide annually, while cancer-related deaths exceed 9 million each year. PET imaging has become an essential tool for early cancer detection, tumor staging, treatment planning, recurrence monitoring, and therapy response evaluation. Approximately 80–90% of PET examinations are performed for oncology applications, making cancer diagnosis the largest market segment. Hybrid PET/CT systems enable clinicians to combine metabolic and anatomical information, significantly improving diagnostic accuracy compared with standalone imaging techniques. Increasing implementation of precision oncology and targeted therapies has further strengthened the demand for PET imaging because physicians require accurate assessment of tumor metabolism before and after treatment. Expanding national cancer screening initiatives, rising investments in oncology centers, and continuous development of novel radiotracers continue supporting long-term growth of the global Positron Emission Tomography market.

Increasing Adoption of Hybrid Imaging Technologies

Technological advancements in hybrid imaging systems continue accelerating growth in the Positron Emission Tomography market. Today, more than 90% of newly installed PET systems globally are integrated PET/CT scanners, while PET/MRI adoption continues expanding in advanced healthcare facilities. Hybrid imaging combines functional metabolic information with detailed anatomical visualization, allowing physicians to diagnose diseases more accurately while reducing examination time. Modern digital PET scanners offer higher image resolution, improved sensitivity, shorter scan durations, and lower radiation exposure compared to earlier generations. Artificial intelligence-assisted image reconstruction, automated lesion detection, and advanced quantitative analysis have further enhanced diagnostic confidence. Healthcare providers increasingly replace aging standalone PET equipment with advanced hybrid systems to improve workflow efficiency and patient outcomes. Growing investments in hospital modernization, imaging infrastructure, and precision medicine programs continue driving replacement demand. Continuous innovation in detector technology, digital photon counting, and software-based image enhancement is expected to sustain robust growth throughout the PET imaging market over the forecast period.

Expanding Applications in Neurology and Cardiology

Although oncology remains the largest application, expanding clinical use in neurology and cardiology is creating significant opportunities for the Positron Emission Tomography market. Neurological disorders affect hundreds of millions of people worldwide, with Alzheimer’s disease, Parkinson’s disease, epilepsy, and dementia becoming increasingly prevalent due to population aging. PET imaging enables physicians to detect metabolic abnormalities in the brain before structural changes become visible using conventional imaging methods. In cardiology, PET is widely used to evaluate myocardial viability, coronary artery disease, myocardial perfusion, and cardiac inflammation. Cardiac PET provides highly accurate quantitative measurements of blood flow, improving treatment planning for complex cardiovascular conditions. The development of disease-specific radiopharmaceuticals has expanded PET applications beyond oncology into neurodegenerative diseases and inflammatory disorders. Increasing healthcare expenditure, growing awareness of early disease diagnosis, and wider availability of advanced PET imaging systems are expected to accelerate adoption across neurology and cardiology, contributing significantly to future market expansion.

Challenge

High Equipment, Installation, and Operational Costs

One of the major challenges facing the Positron Emission Tomography market is the high cost associated with purchasing, installing, and operating PET imaging systems. Advanced digital PET/CT scanners typically require investments of US$2–5 million, while integrated PET/MRI systems often exceed this range due to their complex technology. In addition to equipment costs, healthcare providers must invest in radiation-shielded facilities, cyclotron access or radiopharmaceutical supply networks, quality assurance programs, and highly trained nuclear medicine professionals. Annual maintenance expenses and periodic software upgrades further increase operational costs. Smaller hospitals and diagnostic centers, particularly in low- and middle-income countries, frequently face financial barriers that limit adoption of PET technology. Reimbursement limitations in certain healthcare systems may also discourage investment despite growing clinical demand. The combination of substantial capital expenditure, infrastructure requirements, and specialized workforce needs continues to restrict market penetration, especially in resource-constrained healthcare environments.

Short Half-Life of Radiotracers and Limited Supply Infrastructure

The production and distribution of PET radiopharmaceuticals remain significant operational challenges for the global market. The most widely used PET tracer, Fluorodeoxyglucose (18F-FDG), has a physical half-life of approximately 110 minutes, requiring rapid production, transportation, and administration before radioactive decay reduces its effectiveness. Other PET isotopes such as Carbon-11 have even shorter half-lives of around 20 minutes, making local production essential. As a result, PET imaging centers depend on reliable cyclotron facilities, radiopharmacies, and highly coordinated logistics networks. Delays in production, transportation disruptions, or equipment failures can lead to canceled examinations and increased operating costs. Many developing countries have limited cyclotron infrastructure, restricting access to advanced PET imaging services. Expanding radiopharmaceutical manufacturing capacity, improving distribution networks, and developing longer-lasting tracers remain key priorities for overcoming supply constraints and supporting broader adoption of Positron Emission Tomography worldwide.

Positron Emission Tomography Launches Worldwide

• June 2026 – Siemens Healthineers launched the Biograph Vision.X PET/CT, featuring enhanced digital detector technology, AI-powered image reconstruction, and faster whole-body scanning for oncology and cardiology applications.
• April 2026 – GE HealthCare introduced the Omni Legend Elite PET/CT, offering improved time-of-flight (TOF) imaging, lower radiation dose, and enhanced workflow automation for diagnostic imaging centers.
• February 2026 – United Imaging Healthcare launched the uMI Panorama Digital PET/CT, incorporating ultra-high sensitivity detectors and artificial intelligence-assisted image processing for precision diagnostics.
• November 2025 – Philips Healthcare introduced its next-generation Digital PET/CT Platform, designed to improve lesion detection, accelerate scan times, and enhance quantitative imaging performance.
• September 2025 – Canon Medical Systems launched the Celesteion PET/CT Advanced Edition, featuring upgraded reconstruction algorithms, improved patient throughput, and optimized oncology imaging workflows.
• July 2025 – Positron Corporation launched the latest Attrius PET Imaging System, incorporating enhanced cardiac imaging capabilities and advanced quantitative analysis for nuclear cardiology.
• May 2025 – Neusoft Medical Systems introduced the NeuSight Digital PET/CT, integrating AI-based image optimization, high-resolution detectors, and low-dose scanning protocols for oncology and neurological imaging.
• March 2025 – Bruker launched a new Preclinical PET/MRI Imaging Platform, supporting pharmaceutical research, molecular imaging, and translational medicine with enhanced multimodal imaging capabilities.
• October 2024 – United Imaging Healthcare introduced the uEXPLORER Total-Body PET/CT Upgrade Package, delivering extended axial field-of-view imaging, significantly faster examinations, and improved tracer sensitivity for research and clinical applications.
• June 2024 – Siemens Healthineers expanded its Biograph Trinion PET/CT portfolio globally with upgraded digital workflow software, AI-assisted image reconstruction, and advanced oncology imaging applications for hospitals and diagnostic centers.

Full-Ring PET Scanners Market – Advanced Imaging Performance Driving Market Growth

The Full-Ring PET Scanners market is expanding steadily due to increasing demand for high-resolution molecular imaging in oncology, neurology, and cardiology. Full-ring PET systems utilize detector arrays arranged in a complete circular configuration, enabling 360-degree image acquisition with superior sensitivity and faster scan times compared to partial-ring systems. These scanners account for an estimated over 90% of newly installed PET systems worldwide, reflecting their widespread adoption in hospitals and diagnostic imaging centers. Digital detector technology, time-of-flight (TOF) imaging, and artificial intelligence-assisted image reconstruction have significantly improved lesion detectability while reducing radiation exposure. Healthcare providers continue replacing older analog systems with digital full-ring PET/CT and PET/MRI scanners to enhance workflow efficiency and diagnostic accuracy. Growing investments in cancer treatment centers, precision medicine, and advanced diagnostic infrastructure further support market demand. Continuous technological innovation, improved detector materials, and expanding reimbursement coverage are expected to sustain long-term growth in the Full-Ring PET Scanners market globally.

Bismuth Germanium Oxide Market – Reliable Scintillation Material Supporting PET Imaging

The Bismuth Germanium Oxide (BGO) market remains an important segment within PET imaging detector materials due to its excellent gamma-ray stopping power and stable scintillation characteristics. BGO crystals have historically been widely used in PET scanners because of their high density of approximately 7.13 g/cm³, allowing efficient detection of high-energy gamma photons emitted during positron annihilation. Although newer scintillation materials have gained popularity, BGO continues to be utilized in many installed PET systems and research applications because of its durability, radiation resistance, and cost-effectiveness. Manufacturers continue improving crystal production quality to enhance imaging performance and detector reliability. Academic research institutions and selected healthcare facilities continue operating PET systems equipped with BGO detectors for routine clinical imaging and scientific investigations. Demand is also supported by equipment maintenance and replacement requirements for existing imaging systems. Continued technological improvements and specialized applications are expected to maintain stable demand within the Bismuth Germanium Oxide market.

Lutetium Fine Silicate Market – High-Performance Detector Materials Accelerating Adoption

The Lutetium Fine Silicate market is experiencing significant growth as healthcare providers increasingly adopt advanced PET scanners equipped with high-performance scintillation crystals. Lutetium-based detector materials, including lutetium oxyorthosilicate (LSO) and lutetium yttrium oxyorthosilicate (LYSO), offer faster light output, higher sensitivity, and shorter decay times than traditional detector materials. These crystals are now incorporated into approximately 70–80% of newly installed premium PET systems, supporting superior image quality and reduced examination times. High stopping efficiency and compatibility with time-of-flight (TOF) imaging enable improved lesion detection and quantitative imaging performance. Digital PET systems utilizing lutetium-based crystals provide greater diagnostic confidence while lowering radiation doses for patients. Growing demand for precision oncology, neurological imaging, and cardiovascular diagnostics continues increasing adoption across hospitals and diagnostic centers. Ongoing investments in crystal manufacturing technologies and next-generation detector development are expected to further strengthen the Lutetium Fine Silicate market over the coming years.

Cardiology Positron Emission Tomography Market – Increasing Cardiovascular Disease Burden Supporting Growth

The Cardiology Positron Emission Tomography market is expanding due to the growing prevalence of cardiovascular diseases and increasing demand for accurate non-invasive diagnostic imaging. Cardiovascular disorders remain responsible for approximately 18–20 million deaths annually worldwide, encouraging greater adoption of advanced cardiac imaging technologies. Cardiac PET enables highly accurate assessment of myocardial perfusion, coronary blood flow, myocardial viability, inflammation, and ischemia. Compared with conventional nuclear imaging, PET offers superior image resolution, quantitative blood flow analysis, and shorter imaging procedures. Hospitals increasingly utilize PET for evaluating patients with complex coronary artery disease, heart failure, and prior myocardial infarction. Integration of PET with CT provides comprehensive anatomical and functional assessment, improving treatment planning and patient management. Expanding investments in specialized cardiac centers, growing awareness of early cardiovascular diagnosis, and continuous development of dedicated cardiac radiotracers continue driving long-term growth in the Cardiology Positron Emission Tomography market worldwide.

Positron Emission Tomography Diagnostic Centers Market – Expanding Imaging Infrastructure Driving Demand

The Positron Emission Tomography Diagnostic Centers market continues growing as healthcare systems expand access to advanced molecular imaging services. Dedicated diagnostic imaging centers now perform an estimated 40–50% of global PET examinations, complementing hospital-based nuclear medicine departments. Increasing cancer incidence, neurological disorders, and cardiovascular diseases continue driving patient referrals for PET imaging. Independent diagnostic centers invest in modern PET/CT and PET/MRI systems to provide high-quality imaging while improving patient throughput and reducing waiting times. Digital workflow solutions, AI-assisted image analysis, electronic health record integration, and automated scheduling systems further enhance operational efficiency. Many centers are expanding radiopharmaceutical capabilities through partnerships with regional cyclotrons and radiopharmacies, ensuring reliable tracer availability. Growing outpatient imaging demand, favorable reimbursement in several healthcare markets, and increasing physician preference for early disease detection continue supporting expansion. Continuous investment in advanced equipment, skilled nuclear medicine professionals, and precision diagnostics is expected to sustain long-term growth in the Positron Emission Tomography Diagnostic Centers market.

United States Positron Emission Tomography Market – Advanced Healthcare Infrastructure Driving Market Leadership

The United States represents the largest Positron Emission Tomography (PET) market globally, supported by advanced healthcare infrastructure, extensive diagnostic imaging capacity, and high adoption of precision medicine. The country operates more than 2,500 PET and PET/CT imaging systems, with oncology accounting for approximately 80–85% of PET examinations. Hospitals and independent diagnostic imaging centers continue investing in digital PET/CT and PET/MRI technologies to improve diagnostic accuracy and workflow efficiency. Rising cancer prevalence, increasing neurological disorders, and expanding cardiovascular disease management continue driving procedure volumes. The widespread availability of cyclotrons, radiopharmacies, and specialized nuclear medicine professionals ensures reliable access to PET imaging nationwide. Artificial intelligence-assisted image reconstruction, time-of-flight (TOF) imaging, and advanced radiotracer development continue improving clinical outcomes. Growing investments in personalized oncology, pharmaceutical research, and hybrid imaging technologies further strengthen market expansion. Continuous replacement of aging imaging equipment and favorable reimbursement for several PET applications continue supporting long-term growth in the United States PET market.

United Kingdom Positron Emission Tomography Market – NHS Expansion Supporting Molecular Imaging

The United Kingdom Positron Emission Tomography market is steadily expanding as the National Health Service (NHS) continues investing in advanced diagnostic imaging to improve early disease detection. The country operates more than 70 PET imaging facilities, serving patients across oncology, neurology, and cardiology. Cancer imaging represents approximately 75–80% of total PET scan utilization, with PET/CT becoming a standard component of diagnosis, staging, and treatment monitoring for many malignancies. Healthcare providers continue expanding access to digital PET scanners with improved detector technology and lower radiation exposure. Increasing demand for Alzheimer’s disease assessment, epilepsy diagnosis, and cardiac viability studies further supports market growth. Research institutions are also actively developing novel radiopharmaceuticals for precision medicine applications. Continued investment in imaging infrastructure, workforce training, and regional diagnostic centers improves patient accessibility. Ongoing modernization of healthcare services and increasing adoption of artificial intelligence for image analysis continue strengthening the United Kingdom PET market.

India Positron Emission Tomography Market – Expanding Cancer Care Infrastructure Accelerating Growth

India’s Positron Emission Tomography market is experiencing rapid growth due to expanding healthcare infrastructure, increasing cancer incidence, and greater investment in advanced diagnostic technologies. The country has more than 450 PET/CT scanners installed across government hospitals, private healthcare institutions, and specialized diagnostic centers, with new installations increasing annually. Oncology accounts for approximately 85–90% of PET procedures, reflecting the growing demand for accurate cancer diagnosis and treatment monitoring. Major metropolitan cities including Delhi, Mumbai, Bengaluru, Hyderabad, Chennai, and Kolkata continue expanding nuclear medicine capabilities and radiopharmaceutical production facilities. Private healthcare providers are investing in digital PET systems, artificial intelligence-assisted image processing, and high-throughput diagnostic centers to improve operational efficiency. Government initiatives supporting cancer screening and healthcare modernization have also increased access to molecular imaging services. Rising awareness of early disease detection, expanding medical tourism, and increasing availability of fluorodeoxyglucose (FDG) radiotracers continue driving strong long-term growth in India’s Positron Emission Tomography market.

Saudi Arabia Positron Emission Tomography Market – Healthcare Modernization Supporting Advanced Diagnostics

Saudi Arabia’s Positron Emission Tomography market is expanding rapidly as the Kingdom strengthens its healthcare sector through major investments under Vision 2030. Leading tertiary hospitals and specialized oncology centers continue adopting advanced PET/CT systems to improve cancer diagnosis and personalized treatment planning. Oncology represents approximately 80–85% of PET imaging procedures, while neurological and cardiovascular applications are steadily increasing. Major healthcare facilities in Riyadh, Jeddah, Dammam, and Medina continue expanding molecular imaging capabilities alongside radiopharmaceutical production and nuclear medicine departments. Investments in digital healthcare infrastructure, artificial intelligence-assisted diagnostics, and hybrid imaging technologies are improving diagnostic accuracy and patient care. The country is also increasing training programs for nuclear medicine physicians, radiologists, and medical physicists to strengthen workforce capacity. Growing prevalence of chronic diseases, expanding private healthcare investment, and increasing demand for precision medicine continue supporting long-term growth of the Saudi Arabian Positron Emission Tomography market.

Research Methodology of the Positron Emission Tomography Market

1. Define the Market Scope

• The Positron Emission Tomography (PET) Market is estimated using a bottom-up procedure-volume and equipment approach, followed by vendor-revenue cross-validation.
• First define whether the study covers:
  • PET imaging equipment only.
  • PET imaging equipment + radiopharmaceuticals.
  • PET diagnostic imaging services.
  • Maintenance, software, installation, and training.
• PET should be clearly differentiated from broader nuclear medicine, CT, MRI, and general diagnostic imaging markets.

2. Estimate the PET Scanner Market

• Calculate the equipment market using: PET Equipment Market = Number of PET Scanners Sold × Average Selling Price
• Annual scanner sales include both new installations and replacements: Annual Scanner Sales = New Scanner Installations + Replacement Scanners
• Therefore: PET Equipment Revenue = Annual Scanner Sales × Average Selling Price
• Develop separate ASP assumptions for:
  • Standalone PET
  • PET/CT
  • PET/MRI
  • Digital PET/CT
  • Total-body PET
• PET systems detect positron-emitting radiopharmaceuticals and generate tomographic images.

3. Build the PET Installed-Base Model

• Establish the existing PET scanner base by country and region.
• Calculate replacement requirements: Replacement Demand = Installed PET Base × Annual Replacement Rate
• Estimate new installations: New Demand = Additional Facilities × Average Scanners per Facility
• Therefore: Total Annual Scanner Demand = Replacement Demand + New Demand
• Use nuclear medicine facility databases, national healthcare statistics, hospital databases, and equipment-provider information to establish the installed base.
• The IAEA Nuclear Medicine Database can support information on nuclear medicine facilities, PET scanners, cyclotrons, radiopharmaceuticals, and procedures, but its voluntarily supplied data should be cross-checked with national sources.

4. Estimate the PET Imaging Services Market

• If diagnostic PET services are included, estimate: PET Imaging Services Market = Number of PET Examinations × Average Revenue per Examination
• PET examination volumes can be derived from scanner utilization: PET Scans = Number of PET Scanners × Scans per Scanner per Day × Operating Days × Utilization Rate
• Validate procedure volumes using hospitals, nuclear medicine centers, reimbursement databases, healthcare statistics, and national procedure data.

5. Estimate the PET Radiopharmaceutical Market

• Calculate the radiopharmaceutical component separately because PET examinations require specific radioactive tracers.
• The basic formula is: PET Radiopharmaceutical Market = Number of Doses × Average Revenue per Dose
• Segment radiopharmaceuticals by tracer and application:

• FDA historical data reported approximately 2.495 million PET scans in the United States in 2022, with FDG accounting for approximately 82% of scans.
• These figures should be treated as historical U.S. benchmarks and used for validation rather than as current global market data.

6. Calculate Radiopharmaceutical Consumption

• Develop a detailed dose-based model: Annual Doses = PET Scans × Average Doses per Scan
• Then calculate: Radiopharmaceutical Revenue = Annual Doses × Average Selling Price
• Segment the supply structure into:
  • Hospital-based radiopharmacies
  • Commercial radiopharmacies
  • Cyclotron-produced tracers
  • Generator-produced tracers
• Consider isotope half-life, production location, transportation distance, cyclotron availability, radiopharmacy infrastructure, and local distribution when estimating geographic markets.
• Short-lived PET isotopes make production and distribution infrastructure particularly important.

7. Estimate the Market by Application

• Calculate application-level revenue using: Application Market = PET Procedures × Average Revenue per Procedure

Oncology

• Initial cancer diagnosis
• Staging
• Restaging
• Treatment monitoring
• Recurrence detection

Neurology

• Alzheimer's/dementia imaging
• Epilepsy
• Brain disorders
• Amyloid imaging

Cardiology

• Myocardial perfusion
• Myocardial viability
• Cardiac metabolism
• FDA PET-drug information can be used to validate the use of PET imaging in cancer, neurological, and cardiac applications.

8. Estimate PET/CT Separately

• PET/CT should be separately analyzed because it integrates PET and CT technologies.
• The calculation can be structured as: PET/CT Market = PET Component + CT Component + Integrated System Revenue
• However, the entire CT market should not be added to the PET market.
• Only the portion of the integrated PET/CT system attributable to PET-related equipment should be included when the report specifically measures the PET market.
• Maintain consistency in allocating integrated-system revenue to avoid double counting.

9. Estimate Maintenance, Software, and Recurring Revenue

• Include recurring revenue streams where they fall within the market scope:
  • Preventive maintenance
  • Repairs
  • Replacement parts
  • Software upgrades
  • Image reconstruction software
  • Service contracts
  • Installation
  • Training
• Calculate recurring service revenue as: PET Equipment Service Market = Installed Scanner Base × Average Annual Service Revenue per Scanner
• This provides a recurring-revenue component in addition to scanner sales.

10. Validate Through Vendor Revenue

• Identify PET-related revenues from major imaging equipment manufacturers, including:
  • Siemens Healthineers
  • GE HealthCare
  • Philips
  • United Imaging Healthcare
  • Canon Medical Systems
• Separately identify companies and radiopharmacy providers involved in PET radiopharmaceuticals.
• Do not use the complete revenue of diversified companies.
• Allocate only the PET-related portion: PET Revenue = Company Revenue × Estimated PET Revenue Share
• Compare vendor-derived revenue against the bottom-up estimate.
• Investigate major differences before finalizing the market size.

11. Estimate the Market by Geography

• Develop estimates for:
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa
• For each country, collect:
  • PET scanners
  • PET facilities
  • PET examinations
  • Radiopharmaceutical consumption
  • Healthcare expenditure
• Country-level market value can be calculated as: Country PET Market = Equipment Revenue + Radiopharmaceutical Revenue + PET Service Revenue + Maintenance/Software Revenue
• Regional market value is then: Regional Market = Σ Country Markets

12. Segment by Equipment Type

• Separate equipment demand by:
  • Standalone PET
  • PET/CT
  • PET/MRI
  • Digital PET/CT
  • Total-body PET
• Assess each segment according to:
  • Installed base
  • New installations
  • Replacement cycles
  • Scanner utilization
  • ASP
  • Hospital investment
  • Technology adoption

13. Segment by Procedure Volume

• Estimate PET procedure volumes by:
  • Oncology
  • Neurology
  • Cardiology
  • Other applications
• For each application, assess:
  • Number of procedures
  • Procedures per scanner
  • Scanner utilization
  • Average revenue per procedure
  • Reimbursement availability
  • Patient demand

14. Validate PET Infrastructure and Capacity

• Cross-check scanner numbers with:
  • PET facilities
  • Nuclear medicine departments
  • Hospitals
  • Cyclotrons
  • Radiopharmacies
  • Imaging centers
  • Public and private healthcare infrastructure
• Use facility-level information to identify whether reported scanner numbers represent active, installed, or operational equipment.

15. Validate the Market Through Healthcare Expenditure

• Use healthcare expenditure as a top-down validation layer.
• Assess:
  • Diagnostic imaging expenditure
  • Nuclear medicine expenditure
  • Oncology expenditure
  • Neurology expenditure
  • Cardiology expenditure
  • Government healthcare spending
  • Private healthcare spending
• Compare the resulting PET expenditure with the equipment, procedure, and radiopharmaceutical estimates.

16. Forecast the PET Equipment Market, 2026–2034

• Forecast scanner units and ASP separately rather than applying a single growth rate.
• Key equipment drivers include:
  • New hospital construction
  • PET scanner replacement
  • Digital PET adoption
  • Total-body PET adoption
  • PET/CT upgrades
  • Increasing imaging capacity
• Calculate: Future PET Equipment Market = Future Scanner Sales × Future ASP

17. Forecast PET Procedure Volumes

• Forecast PET examinations based on:
  • Cancer incidence
  • Neurological disease diagnosis
  • Cardiovascular disease
  • PET adoption
  • Healthcare expenditure
  • Reimbursement availability
  • Scanner availability
  • Patient awareness
• The procedure-based forecast is: Future PET Service Market = Future PET Scans × Future Revenue per Scan

18. Forecast the Radiopharmaceutical Market

• Forecast PET tracer demand based on:
  • PET scan volumes
  • New tracer approvals
  • PSMA adoption
  • Amyloid imaging
  • Radiopharmacy expansion
  • Isotope availability
  • Cyclotron capacity
  • Increasing oncology applications
• Calculate: Future Radiopharmaceutical Market = Future PET Doses × Future Revenue per Dose

19. Apply the Overall Market Forecast

• The basic market forecasting formula is: Future Market = Base-Year Market × (1 + CAGR) ^n
• For a stronger Renub Research model, forecast the underlying variables independently:
  • Scanner units
  • Scanner ASP
  • PET examinations
  • Revenue per examination
  • Radiopharmaceutical doses
  • Revenue per dose
  • Service revenue per installed scanner
• The resulting component forecasts are then aggregated to derive the total PET market.

20. Historical Market Estimation

• Calculate historical market values using: Historical Market Value = Historical Volume × Historical ASP
• Historical analysis should consider:
  • PET scanner installations
  • Replacement activity
  • PET/CT adoption
  • PET procedure volumes
  • FDG utilization
  • Growth of specialty tracers
  • Radiopharmacy infrastructure
  • Healthcare expenditure
  • Reimbursement changes
  • Technology upgrades

21. Three-Method Market Triangulation

• Apply three independent estimation approaches.

Method 1 — Equipment-Based

• PET Scanner Sales × Average Selling Price

Method 2 — Procedure-Based

• PET Scans × Average Revenue per Scan

Method 3 — Radiopharmaceutical-Based

• PET Doses × Average Revenue per Dose
• Use the following as independent validation layers:
  • Manufacturer revenues
  • Radiopharmaceutical company revenues
  • Healthcare expenditure
  • PET facilities
  • Scanner installed base
  • Procedure volumes
  • Cyclotron and radiopharmacy infrastructure
• The three methods should not simply be added together, as they represent overlapping components of the broader PET ecosystem.
• Instead, reconcile the estimates according to the defined market scope and use the other approaches as validation checks.

22. Final Market Calculation Framework

Depending on the selected market definition, the final model can be structured as:

• PET Equipment Market = New Scanner Revenue + Replacement Scanner Revenue
• PET Imaging Services Market = PET Procedures × Average Revenue per Procedure
• PET Radiopharmaceutical Market = PET Doses × Average Revenue per Dose
• PET Service Market = Installed Scanner Base × Annual Service Revenue per Scanner

For a broader PET ecosystem: Total PET Market = Equipment + Radiopharmaceuticals + Imaging Services + Maintenance/Software

The final market size is reconciled using bottom-up demand, installed infrastructure, procedure volumes, radiopharmaceutical consumption, vendor revenues, and healthcare expenditure to minimize double counting and improve estimate reliability.

Market Segmentation

Product Type

• Full-Ring PET Scanners
• Partial-Ring PET Scanners

Detector Type

• Bismuth Germanium Oxide
• Lutetium Oxyorthosilicate
• Lutetium Fine Silicate
• Lutetium Yttrium Orthosilicate
• Gadolinium Oxyorthosilicate

Application

• Cardiology
• Neurology
• Oncology
• Others

End-User

• Hospitals and Clinics
• Diagnostic Centers
• Others

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• South Korea
• Thailand
• Malaysia
• Indonesia
• Australia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• Saudi Arabia
• UAE
• South Africa

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Agfa Healthcare (Dedalus Group)
• GE Healthcare
• Koninklijke Philips NV
• Neusoft Medical Systems
• Positron Corporation
• Oncovision (Bruker)
• Mediso Medical Imaging Systems Ltd.
• Siemens Healthineers AG
• Segami Corporation
• Hitachi Ltd.

Report Details: